Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Treatment and survival of glioblastoma patients in Denmark: The Danish Neuro-Oncology Registry 2009-2014.

Hansen S, Rasmussen BK, Laursen RJ, Kosteljanetz M, Schultz H, Nørgård BM, Guldberg R, Gradel KO.

J Neurooncol. 2018 Sep;139(2):479-489. doi: 10.1007/s11060-018-2892-7. Epub 2018 May 12.

PMID:
29754199
2.

Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan.

Toft A, Urup T, Christensen IJ, Michaelsen SR, Lukram B, Grunnet K, Kosteljanetz M, Larsen VA, Lassen U, Broholm H, Poulsen HS.

Cancer Invest. 2018 Feb 7;36(2):165-174. doi: 10.1080/07357907.2018.1430818. Epub 2018 Feb 2. Review.

PMID:
29393706
3.

Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry.

Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, Nørgård BM, Guldberg R, Gradel KO.

J Neurooncol. 2017 Dec;135(3):571-579. doi: 10.1007/s11060-017-2607-5. Epub 2017 Aug 31.

PMID:
28861666
4.

Prevalence, birth incidence, and penetrance of von Hippel-Lindau disease (vHL) in Denmark.

Binderup ML, Galanakis M, Budtz-Jørgensen E, Kosteljanetz M, Luise Bisgaard M.

Eur J Hum Genet. 2017 Feb;25(3):301-307. doi: 10.1038/ejhg.2016.173. Epub 2016 Dec 14.

5.

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.

Urup T, Michaelsen SR, Olsen LR, Toft A, Christensen IJ, Grunnet K, Winther O, Broholm H, Kosteljanetz M, Issazadeh-Navikas S, Poulsen HS, Lassen U.

Mol Oncol. 2016 Oct;10(8):1160-8. doi: 10.1016/j.molonc.2016.05.005. Epub 2016 May 26.

6.

Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.

Urup T, Dahlrot RH, Grunnet K, Christensen IJ, Michaelsen SR, Toft A, Larsen VA, Broholm H, Kosteljanetz M, Hansen S, Poulsen HS, Lassen U.

Acta Oncol. 2016;55(4):418-22. doi: 10.3109/0284186X.2015.1114679. Epub 2016 Feb 1.

PMID:
26828563
7.

Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition.

Binderup ML, Bisgaard ML, Harbud V, Møller HU, Gimsing S, Friis-Hansen L, Hansen Tv, Bagi P, Knigge U, Kosteljanetz M, Bøgeskov L, Thomsen C, Gerdes AM, Ousager LB, Sunde L; Danish vHL Coordination Group.

Dan Med J. 2013 Dec;60(12):B4763.

PMID:
24355456
8.

Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution.

Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M, Poulsen HS.

BMC Cancer. 2013 Sep 3;13:402. doi: 10.1186/1471-2407-13-402.

9.

von Hippel-Lindau disease: deafness due to a non-MRI-visible endolymphatic sac tumor despite targeted screening.

Binderup ML, Gimsing S, Kosteljanetz M, Thomsen C, Bisgaard ML.

Int J Audiol. 2013 Nov;52(11):771-5. doi: 10.3109/14992027.2013.824117. Epub 2013 Sep 5.

PMID:
24003980
10.

[Danish Neuro-Oncology Registry].

Hansen S, Green A, Nielsen J, Haugaard M, Laursen R, Schultz H, Rasmussen B, Broholm H, Andersen P, Kosteljanetz M; styregruppen for DNOR.

Ugeskr Laeger. 2012 Oct 15;174(42):2558. Danish. No abstract available.

PMID:
23079461
11.

Brain perfusion CT compared with ¹⁵O-H₂O PET in patients with primary brain tumours.

Grüner JM, Paamand R, Kosteljanetz M, Broholm H, Højgaard L, Law I.

Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1691-701. doi: 10.1007/s00259-012-2173-1. Epub 2012 Jun 27.

12.

[Cancer packages: Does haste lead to more work?].

Kosteljanetz M.

Ugeskr Laeger. 2012 Jun 11;174(24):1657. Danish. No abstract available.

PMID:
22681988
13.

von Hippel-Lindau disease: surveillance strategy for endolymphatic sac tumors.

Poulsen ML, Gimsing S, Kosteljanetz M, Møller HU, Brandt CA, Thomsen C, Bisgaard ML.

Genet Med. 2011 Dec;13(12):1032-41. doi: 10.1097/GIM.0b013e31822beab1.

PMID:
21912262
14.

Common variation at 10p12.31 near MLLT10 influences meningioma risk.

Dobbins SE, Broderick P, Melin B, Feychting M, Johansen C, Andersson U, Brännström T, Schramm J, Olver B, Lloyd A, Ma YP, Hosking FJ, Lönn S, Ahlbom A, Henriksson R, Schoemaker MJ, Hepworth SJ, Hoffmann P, Mühleisen TW, Nöthen MM, Moebus S, Eisele L, Kosteljanetz M, Muir K, Swerdlow A, Simon M, Houlston RS.

Nat Genet. 2011 Jul 31;43(9):825-7. doi: 10.1038/ng.879.

15.

Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin-1β and inhibited by growth hormone releasing hormone and somatostatin.

Vindeløv SD, Hartoft-Nielsen ML, Rasmussen ÅK, Bendtzen K, Kosteljanetz M, Andersson AM, Feldt-Rasmussen U.

Growth Horm IGF Res. 2011 Jun;21(3):134-9. doi: 10.1016/j.ghir.2011.03.005.

PMID:
21658592
16.

Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.

Stockhausen MT, Broholm H, Villingshøj M, Kirchhoff M, Gerdes T, Kristoffersen K, Kosteljanetz M, Spang-Thomsen M, Poulsen HS.

Exp Cell Res. 2011 Jul 1;317(11):1513-26. doi: 10.1016/j.yexcr.2011.04.001. Epub 2011 Apr 15.

PMID:
21514294
17.

Letter to the editor.

Kosteljanetz M.

Neuroradiol J. 2010 Oct;23(5):633. Epub 2010 Oct 31. No abstract available.

PMID:
24148687
18.

An evaluation of the Danish national clinical guidelines for von Hippel-Lindau (VHL).

Bertelsen M, Kosteljanetz M.

Acta Neurochir (Wien). 2011 Jan;153(1):35-41; discussion 41. doi: 10.1007/s00701-010-0786-3. Epub 2010 Sep 25.

PMID:
20865287
19.

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS.

Neuro Oncol. 2010 May;12(5):508-16. doi: 10.1093/neuonc/nop063. Epub 2010 Feb 5.

20.

Fractionated stereotactic radiotherapy in patients with acromegaly: an interim single-centre audit.

Roug S, Rasmussen AK, Juhler M, Kosteljanetz M, Poulsgaard L, Heebøll H, Roed H, Feldt-Rasmussen U.

Eur J Endocrinol. 2010 Apr;162(4):685-94. doi: 10.1530/EJE-09-1045. Epub 2010 Feb 4.

PMID:
20133445
21.

Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage.

Klose M, Brennum J, Poulsgaard L, Kosteljanetz M, Wagner A, Feldt-Rasmussen U.

Clin Endocrinol (Oxf). 2010 Jul;73(1):95-101. doi: 10.1111/j.1365-2265.2010.03791.x. Epub 2010 Jan 23.

PMID:
20105184
22.

[Chemotherapeutic wafers in treatment of malignant cerebral glioma. Assessment of a Cochrane review].

Kosteljanetz M, Poulsen HS.

Ugeskr Laeger. 2010 Jan 18;172(3):214-7. Review. Danish.

PMID:
20089214
23.

Incidence of and survival from oligodendroglioma in Denmark, 1943-2002.

Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C.

Neuro Oncol. 2009 Jun;11(3):311-7. doi: 10.1215/15228517-2008-105. Epub 2008 Dec 9.

24.

Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours.

Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, Kosteljanetz M, Lassen U.

Acta Oncol. 2009;48(1):52-8. doi: 10.1080/02841860802537924.

PMID:
19031176
25.

Anterior cervical discectomy with or without fusion with ray titanium cage: a prospective randomized clinical study.

Hauerberg J, Kosteljanetz M, Bøge-Rasmussen T, Dons K, Gideon P, Springborg JB, Wagner A.

Spine (Phila Pa 1976). 2008 Mar 1;33(5):458-64. doi: 10.1097/BRS.0b013e3181657dac.

PMID:
18317187
26.

Comprehensive analysis of DNA repair gene variants and risk of meningioma.

Bethke L, Murray A, Webb E, Schoemaker M, Muir K, McKinney P, Hepworth S, Dimitropoulou P, Lophatananon A, Feychting M, Lönn S, Ahlbom A, Malmer B, Henriksson R, Auvinen A, Kiuru A, Salminen T, Johansen C, Christensen HC, Kosteljanetz M, Swerdlow A, Houlston R.

J Natl Cancer Inst. 2008 Feb 20;100(4):270-6. doi: 10.1093/jnci/djn004. Epub 2008 Feb 12.

PMID:
18270339
27.

[Post-dural headache?].

Kosteljanetz M.

Ugeskr Laeger. 2007 Dec 17;169(51):4478; author reply 4478. Danish. No abstract available.

PMID:
18213911
28.

Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study.

Klose M, Juul A, Struck J, Morgenthaler NG, Kosteljanetz M, Feldt-Rasmussen U.

Clin Endocrinol (Oxf). 2007 Oct;67(4):598-606.

PMID:
17880406
29.

Prevalence and predictive factors of post-traumatic hypopituitarism.

Klose M, Juul A, Poulsgaard L, Kosteljanetz M, Brennum J, Feldt-Rasmussen U.

Clin Endocrinol (Oxf). 2007 Aug;67(2):193-201. Epub 2007 May 24.

PMID:
17524035
30.

[Neurosurgery: neuro-oncologic quality development. The Danish Society of Neurosurgery].

Kosteljanetz M; Dansk Neurokirurgisk Selskab.

Ugeskr Laeger. 2007 Mar 19;169(12):1123. Danish. No abstract available.

PMID:
17394834
31.

[Use of rating scales with adult brain tumour patients].

Christiansen H, Kosteljanetz M.

Ugeskr Laeger. 2007 Feb 12;169(7):586-90. Review. Danish.

PMID:
17311750
32.

[Pituitary insufficiency following head trauma].

Klose MC, Juul A, Poulsgaard L, Kosteljanetz M, Brennum J, Feldt-Rasmussen UF.

Ugeskr Laeger. 2007 Jan 15;169(3):211-3. Review. Danish.

PMID:
17234095
33.

A prospective PET study of patients with glioblastoma multiforme.

Andersen PB, Blinkenberg M, Lassen U, Kosteljanetz M, Wagner A, Poulsen HS, Sørensen PS, Paulson OB.

Acta Neurol Scand. 2006 Jun;113(6):412-8.

PMID:
16674608
34.

[Lumbar puncture 2].

Astradsson A, Dons K, Gjerris F, Hauerberg J, Jørgensen L, Juhler M, Kosteljanetz M, Møller CM, Bøg-Rasmussen T.

Ugeskr Laeger. 2006 Feb 6;168(6):595-6. Danish. No abstract available.

PMID:
16476228
35.

Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test.

Klose M, Lange M, Kosteljanetz M, Poulsgaard L, Feldt-Rasmussen U.

Clin Endocrinol (Oxf). 2005 Nov;63(5):499-505.

PMID:
16268800
36.

Cellular telephones and risk for brain tumors: a population-based, incident case-control study.

Christensen HC, Schüz J, Kosteljanetz M, Poulsen HS, Boice JD Jr, McLaughlin JK, Johansen C.

Neurology. 2005 Apr 12;64(7):1189-95. Erratum in: Neurology. 2005 Oct 25;65(8):1324.

PMID:
15824345
37.

Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue.

Petersen G, Moesgaard B, Schmid PC, Schmid HH, Broholm H, Kosteljanetz M, Hansen HS.

J Neurochem. 2005 Apr;93(2):299-309.

38.

Brain metastases with unknown primary tumours.

Kosteljanetz M.

Acta Neurochir (Wien). 2005 Jan;147(1):110. No abstract available.

PMID:
15614471
39.

Cellular telephone use and risk of acoustic neuroma.

Christensen HC, Schüz J, Kosteljanetz M, Poulsen HS, Thomsen J, Johansen C.

Am J Epidemiol. 2004 Feb 1;159(3):277-83.

PMID:
14742288
40.

[Brain death criterion--an ethical challenge].

Kosteljanetz M, Eskesen VN, Gjerris F.

Ugeskr Laeger. 2003 Dec 8;165(50):4825-6. Danish. No abstract available.

PMID:
14716895
41.

["Lumbar examination" and cauda equina syndrome].

Bøge-Rasmussen T, Dons K, Gjerris F, Hauerberg J, Jubler M, Kosteljanetz M, Møller CM, Nielsen LB, Osgaard O, Poulsgaard L, Westergaard L.

Ugeskr Laeger. 2003 Aug 18;165(34):3249; author reply 3249-50. Danish. No abstract available.

PMID:
12970998
42.

Incidences of gliomas and meningiomas in Denmark, 1943 to 1997.

Christensen HC, Kosteljanetz M, Johansen C.

Neurosurgery. 2003 Jun;52(6):1327-33; discussion 1333-4.

PMID:
12762878
43.
44.

[Brain metastases].

Brennum J, Kosteljanetz M, Roed HM.

Ugeskr Laeger. 2002 Jul 1;164(27):3522-6. Review. Danish.

PMID:
12116679
45.

[Brain tumors. Mainly glial tumors in adults].

Kosteljanetz M.

Ugeskr Laeger. 2002 Jun 3;164(23):3017-20. Danish. No abstract available.

PMID:
12082850
46.

[Endoscopic closure of cranionasal cerebrospinal fluid fistulas with the use of neuronavigation--"Computer Aided Surgery"].

Kosteljanetz M, von Buchwald C, Poulsgård L, Rasmussen N, Wagner A.

Ugeskr Laeger. 2001 Aug 6;163(32):4201-3. Danish.

PMID:
11510239
47.

Incidence and late prognosis of cushing's syndrome: a population-based study.

Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J.

J Clin Endocrinol Metab. 2001 Jan;86(1):117-23.

PMID:
11231987
48.

[Neurosurgery in the year of 2000. The Danish Society of Neurosurgery].

Kosteljanetz M.

Ugeskr Laeger. 2000 Mar 20;162(12):1719. Danish. No abstract available.

PMID:
10745666
49.

Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.

Lassen U, Kristjansen PE, Wagner A, Kosteljanetz M, Poulsen HS.

J Neurooncol. 1999 Jun;43(2):161-6. Erratum in: J Neurooncol. 2003 May;62(3):361.

PMID:
10533728
50.

[Should "Memento" be anonymous?].

Gjerris F, Kosteljanetz M.

Ugeskr Laeger. 1998 Nov 30;160(49):7148. Danish. No abstract available.

PMID:
9850626

Supplemental Content

Loading ...
Support Center